Syndax Pharmaceuticals will release Q4 and full year 2024 financial results on March 3, 2025, with a conference call.
Quiver AI Summary
Syndax Pharmaceuticals announced that it will release its financial results for the fourth quarter and full year of 2024 on March 3, 2025, and will provide a business update during a conference call that day at 8:00 a.m. ET. The event will be accessible through a live audio webcast and a dedicated phone line. A replay will be available on the company's website for those unable to attend. Syndax is recognized for its innovative cancer therapies, including the FDA-approved menin inhibitor Revuforj® and the CSF-1 receptor-blocking monoclonal antibody Niktimvo™, and is conducting several clinical trials to further its drug pipeline.
Potential Positives
- Syndax Pharmaceuticals is set to report its fourth quarter and full year 2024 financial results, which could provide insights into the company's financial health and performance.
- The announcement includes a conference call and live audio webcast, promoting transparency and engagement with investors and stakeholders.
- The company highlights its innovative pipeline, including two FDA-approved therapies, which showcases its commitment to advancing cancer treatment.
- Syndax's ongoing clinical trials indicate active development and research within its pipeline, underscoring its efforts to enhance cancer care.
Potential Negatives
- Company is announcing its financial results and business update, which can signal potential financial difficulties or shortcomings that may be concerning to investors.
FAQ
When will Syndax report its fourth quarter and full year 2024 financial results?
Syndax will report its financial results on Monday, March 3, 2025.
How can I access the conference call for Syndax's financial results?
You can access the conference call using the Domestic Dial-in Number: 800-590-8290 or International Dial-in Number: 240-690-8800.
Is there a way to watch the live webcast of the earnings call?
Yes, the live audio webcast will be available on the Events & Presentations page on Syndax's website.
Will there be a replay of the financial results call?
A replay will be available on Syndax's website approximately 24 hours after the call and for 90 days thereafter.
What therapies are highlighted in Syndax's pipeline?
Syndax's pipeline includes Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), both FDA-approved therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNDX Insider Trading Activity
$SNDX insiders have traded $SNDX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $SNDX stock by insiders over the last 6 months:
- MICHAEL A METZGER (Chief Executive Officer) sold 13,288 shares for an estimated $206,017
- NEIL GALLAGHER (President, Head of R&D) sold 4,618 shares for an estimated $71,597
- KEITH A. GOLDAN (Chief Financial Officer) sold 3,777 shares for an estimated $58,558
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SNDX Hedge Fund Activity
We have seen 114 institutional investors add shares of $SNDX stock to their portfolio, and 111 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 4,425,677 shares (+498.9%) to their portfolio in Q4 2024, for an estimated $58,507,449
- GOLDMAN SACHS GROUP INC added 4,338,485 shares (+269.1%) to their portfolio in Q4 2024, for an estimated $57,354,771
- EVERSEPT PARTNERS, LP removed 3,761,913 shares (-91.6%) from their portfolio in Q4 2024, for an estimated $49,732,489
- KYNAM CAPITAL MANAGEMENT, LP added 2,677,075 shares (+45.8%) to their portfolio in Q4 2024, for an estimated $35,390,931
- ORBIMED ADVISORS LLC removed 1,925,300 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $25,452,466
- AVORO CAPITAL ADVISORS LLC removed 1,613,437 shares (-41.5%) from their portfolio in Q4 2024, for an estimated $21,329,637
- ASSENAGON ASSET MANAGEMENT S.A. added 1,598,428 shares (+343.0%) to their portfolio in Q4 2024, for an estimated $21,131,218
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss the Company's financial results and provide a business update.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax4Q24
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast:
https://www.veracast.com/webcasts/syndax/events/SNDX4Q24.cfm
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn .
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
SNDX-G
